$TDOC
Teladoc Health, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022006636 Filed on May 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $565.4M $453.7M
YoY Change 24.62% 150.93%
Cost Of Revenue $187.0M $146.0M
YoY Change 28.14% 101.65%
Gross Profit $378.3M $307.7M
YoY Change 22.95% 183.83%
Gross Profit Margin 66.92% 67.83%
Selling, General & Admin $163.3M $170.0M
YoY Change -3.95% 164.41%
% of Gross Profit 43.15% 55.23%
Research & Development $87.41M $78.01M
YoY Change 12.06% 305.09%
% of Gross Profit 23.11% 25.35%
Depreciation & Amortization $58.93M $48.66M
YoY Change 21.11% 401.12%
% of Gross Profit 15.58% 15.81%
Operating Expenses $250.7M $248.0M
YoY Change 1.09% 196.84%
Operating Profit -$6.669B -$84.68M
YoY Change 7776.17% 303.02%
Interest Expense -$5.480M -$22.10M
YoY Change -75.2% 137.63%
% of Operating Profit
Other Income/Expense, Net $724.0K $5.652M
YoY Change -87.19% -925.11%
Pretax Income -$6.674B -$112.6M
YoY Change 5826.77% 271.48%
Income Tax $400.0K $87.00M
% Of Pretax Income
Net Earnings -$6.675B -$199.6M
YoY Change 3243.13% 574.42%
Net Earnings / Revenue -1180.6% -44.01%
Basic Earnings Per Share -$41.58 -$1.31
Diluted Earnings Per Share -$41.58 -$1.31
COMMON SHARES
Basic Shares Outstanding 160.5M 152.2M
Diluted Shares Outstanding 160.5M 152.2M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $839.0M $722.6M
YoY Change 16.1% 41.48%
Cash & Equivalents $836.4M $720.1M
Short-Term Investments $2.544M $2.530M
Other Short-Term Assets $5.326M $73.00M
YoY Change -92.7% 386.67%
Inventory $70.65M $58.29M
Prepaid Expenses $51.40M
Receivables $191.5M $178.3M
Other Receivables $22.82M $0.00
Total Short-Term Assets $1.208B $1.032B
YoY Change 17.02% 73.09%
LONG-TERM ASSETS
Property, Plant & Equipment $28.42M $28.44M
YoY Change -0.06% 181.77%
Goodwill $7.900B $14.45B
YoY Change -45.34% 1867.9%
Intangibles $1.884B $1.997B
YoY Change -5.67% 830.38%
Long-Term Investments
YoY Change
Other Assets $26.63M $28.00M
YoY Change -4.9% 82.66%
Total Long-Term Assets $9.884B $16.55B
YoY Change -40.28% 1544.07%
TOTAL ASSETS
Total Short-Term Assets $1.208B $1.032B
Total Long-Term Assets $9.884B $16.55B
Total Assets $11.09B $17.58B
YoY Change -36.91% 996.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.41M $34.38M
YoY Change 37.92% 322.22%
Accrued Expenses $127.7M $115.0M
YoY Change 11.05% 112.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $12.66M $0.00
YoY Change
Total Short-Term Liabilities $306.7M $260.4M
YoY Change 17.79% 167.96%
LONG-TERM LIABILITIES
Long-Term Debt $1.541B $1.363B
YoY Change 13.06% 204.92%
Other Long-Term Liabilities $1.445M $1.383M
YoY Change 4.48% -86.49%
Total Long-Term Liabilities $1.445M $1.383M
YoY Change 4.48% -86.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $306.7M $260.4M
Total Long-Term Liabilities $1.445M $1.383M
Total Liabilities $308.1M $261.7M
YoY Change 17.72% 143.71%
SHAREHOLDERS EQUITY
Retained Earnings -$8.023B -$1.192B
YoY Change 572.92% 121.98%
Common Stock $17.18B $17.02B
YoY Change 0.94% 982.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.143B $15.83B
YoY Change
Total Liabilities & Shareholders Equity $11.09B $17.58B
YoY Change -36.91% 996.79%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$6.675B -$199.6M
YoY Change 3243.13% 574.42%
Depreciation, Depletion And Amortization $58.93M $48.66M
YoY Change 21.11% 401.12%
Cash From Operating Activities -$31.75M -$18.03M
YoY Change 76.12% 185.22%
INVESTING ACTIVITIES
Capital Expenditures $3.913M $2.115M
YoY Change 85.01% 119.85%
Acquisitions $0.00 $55.92M
YoY Change -100.0% 521.34%
Other Investing Activities -$3.264M -$3.150M
YoY Change 3.62%
Cash From Investing Activities -$27.57M -$16.03M
YoY Change 71.97% 34.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.816M 22.18M
YoY Change -87.3% 47.31%
NET CHANGE
Cash From Operating Activities -31.75M -18.03M
Cash From Investing Activities -27.57M -16.03M
Cash From Financing Activities 2.816M 22.18M
Net Change In Cash -56.50M -11.88M
YoY Change 375.53% 271.86%
FREE CASH FLOW
Cash From Operating Activities -$31.75M -$18.03M
Capital Expenditures $3.913M $2.115M
Free Cash Flow -$35.66M -$20.14M
YoY Change 77.05% 176.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160532301
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152167606
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160469325
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161434513
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-41.58
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001477449
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37477
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
CY2022Q1 dei City Area Code
CityAreaCode
203
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
635-2002
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
TDOC
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161182633
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
836444000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
893480000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2544000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2537000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
13056000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12384000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
191528000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
168956000
CY2022Q1 us-gaap Inventory Net
InventoryNet
70654000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
106875000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
1208045000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1225439000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28419000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27234000
CY2022Q1 us-gaap Goodwill
Goodwill
7899795000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1883897000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1910278000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45552000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46780000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26629000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20703000
CY2022Q1 us-gaap Assets
Assets
11092337000
CY2021Q4 us-gaap Assets
Assets
17734608000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
47412000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47257000
CY2022Q1 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
116689000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
102933000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
46075000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
91941000
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
83847000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
75569000
CY2022Q1 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
12664000
CY2021Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13313000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
306687000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
331013000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1445000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1492000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40163000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41773000
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2884000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3834000
CY2022Q1 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
8252000
CY2021Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9291000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
57516000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
75777000
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1532780000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1225671000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161434513
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160469325
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
161000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
160000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17177152000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17473336000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8023279000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
145959000
CY2022Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
133600000
CY2021Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
89439000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
58933000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1421454000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11424000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6285000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9142610000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11092337000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17734608000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
565350000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
453675000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
187025000
CY2022Q1 us-gaap Selling Expense
SellingExpense
58329000
CY2021Q1 us-gaap Selling Expense
SellingExpense
64793000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87412000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78008000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
104923000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
105172000
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4507000
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
6323000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
48659000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
7234729000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
538353000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6669379000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-84678000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11459000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
724000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5652000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5480000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-22125000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6674135000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112610000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
388000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87039000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5139000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13492000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6679662000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-213141000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-41.58
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58933000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48659000
CY2022Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
770000
CY2021Q1 tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
824000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160532301
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152167606
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3585000
CY2022Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63963000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5139000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9142610000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11908000
CY2021Q1 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2021Q1 tdoc Recovered Excess Common Stock Issued For Acquisition Equity Impact
RecoveredExcessCommonStockIssuedForAcquisitionEquityImpact
40329000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90000000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13492000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15829498000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674523000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-199649000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 tdoc Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment
AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment
3173000
CY2021Q1 tdoc Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment
AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment
2948000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4591000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3074000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
60436000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
86300000
CY2022Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-2319000
CY2021Q1 tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
87004000
CY2022Q1 tdoc Accretion Of Interest
AccretionOfInterest
826000
CY2021Q1 tdoc Accretion Of Interest
AccretionOfInterest
16829000
CY2022Q1 tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
0
CY2021Q1 tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
-11459000
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2021Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
5852000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-38000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27842000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11717000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18993000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12799000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2023000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2877000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6047000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1244000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
492000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11989000
CY2022Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
11706000
CY2021Q1 tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
-1889000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-48819000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-43624000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7479000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17086000
CY2022Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3626000
CY2021Q1 tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3076000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31747000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18026000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3913000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2115000
CY2022Q1 us-gaap Payments For Software
PaymentsForSoftware
26918000
CY2021Q1 us-gaap Payments For Software
PaymentsForSoftware
11144000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
55921000
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3264000
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3150000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27567000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16030000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3585000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11908000
CY2022Q1 tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
0
CY2021Q1 tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
130000
CY2022Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
2232000
CY2021Q1 tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
4816000
CY2022Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
3921000
CY2021Q1 tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
4098000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3680000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8648000
CY2022Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
103000
CY2021Q1 tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
1218000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2863000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-187000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2816000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22175000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-56498000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11881000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-538000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1339000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
893480000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
733324000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
836444000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
720104000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
261000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
52000
CY2022Q1 us-gaap Interest Paid
InterestPaid
7000
CY2021Q1 us-gaap Interest Paid
InterestPaid
3000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of chronic healthcare for individuals around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
CY2022Q1 tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
3
CY2022Q1 tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
12
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the condensed consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Significant estimates and assumptions by management affect areas including the carrying value and useful life of long-lived assets (including intangible assets), the carrying value of goodwill, the capitalization and amortization of software development costs, deferred costs, the allowance for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees, the accounting for income taxes, contingences, litigation and related legal accruals, and the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2021 Form 10-K.</p>
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
565350000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
453675000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
87100000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7600000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18400000
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
51600000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
32700000
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
73200000
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
73000000.0
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5000000.0
CY2022Q1 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
27335000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q1 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
7636000
CY2021Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
6249000
CY2022Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
34971000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
CY2022Q1 tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
13986000
CY2022Q1 tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-7568000
CY2022Q1 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
34971000
CY2022Q1 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
25006000
CY2021Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
26164000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
379000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
313000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
45269000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
46602000
CY2022Q1 us-gaap Inventory Net
InventoryNet
70654000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51397000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38179000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2022Q1 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
27335000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
22817000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
21170000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
5326000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5734000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
106875000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2288059000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
404162000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1883897000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2261768000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
351490000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1910278000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56600000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46600000
CY2022Q1 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategy
5800000
CY2022Q1 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy Per Share
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategyPerShare
0.04
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
64269000
CY2022Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-122306000
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-4379000
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-19044000
CY2022Q1 us-gaap Goodwill
Goodwill
7899795000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2022Q1 tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
41.11
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5485000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5373000
CY2022Q1 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
18029000
CY2021Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
19292000
CY2022Q1 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
10034000
CY2021Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
7653000
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
5809000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5131000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3098000
CY2022Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
5779000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3884000
CY2022Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
6104000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3471000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13052000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12687000
CY2022Q1 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
11429000
CY2021Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
9965000
CY2022Q1 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
5913000
CY2021Q4 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
6263000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29924000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29767000
CY2022Q1 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
116689000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
102933000
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15023000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14261000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9634000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7197000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5822000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12638000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
64575000
CY2022Q1 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
10105000
CY2022Q1 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
8024000
CY2022Q1 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
2678000
CY2022Q1 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
109000
CY2022Q1 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
20916000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60436000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86300000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000000.0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000

Files In Submission

Name View Source Status
0001558370-22-006636-index-headers.html Edgar Link pending
0001558370-22-006636-index.html Edgar Link pending
0001558370-22-006636.txt Edgar Link pending
0001558370-22-006636-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20220331.xsd Edgar Link pending
tdoc-20220331x10q.htm Edgar Link pending
tdoc-20220331x10q_htm.xml Edgar Link completed
tdoc-20220331xex10d1.htm Edgar Link pending
tdoc-20220331xex31d1.htm Edgar Link pending
tdoc-20220331xex31d2.htm Edgar Link pending
tdoc-20220331xex32d1.htm Edgar Link pending
tdoc-20220331xex32d2.htm Edgar Link pending
tdoc-20220331_cal.xml Edgar Link unprocessable
tdoc-20220331_def.xml Edgar Link unprocessable
tdoc-20220331_lab.xml Edgar Link unprocessable
tdoc-20220331_pre.xml Edgar Link unprocessable